Hope is in bloom in RET + NSCLC

Targeted therapies for biomarkers like EGFR, ALK, ROS1, BRAF, NTRK, and now MET and RET are available.1 That's why it's important to:

  1. Identify biomarkers with broad molecular testing like next-generation sequencing (NGS)2
  2. If clinically appropriate, wait for test results to confirm treatment2,3

Identify what drives disease to help confirm your treatment course.

Expert insights: an overview of biomarker testing in metastatic NSCLC with Dr. Timothy Burns, medical oncologist at UPMC Hillman Cancer Center

Watch Now

RET in

Is RET driving disease in some of your patients?

More on RET


NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) recommend testing for RET rearrangements and other biomarkers in eligible patients with metastatic NSCLC.4*†

More on testing

Stay up to date on RET and biomarker testing.



Contact Medical Information at Blueprint Medicines.

Reach Out

  • *The NCCN Guidelines® for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays.
  • The NCCN Guidelines® recommend molecular testing and strongly advise broader molecular profiling, in eligible patients with metastatic NSCLC, with the goal of identifying rare driver mutations for which effective drugs may already be available or to appropriately counsel patients regarding the availability of clinical trials.
  • ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; EGFR=epidermal growth factor receptor; MET=MET proto-oncogene; NCCN=National Comprehensive Cancer Network®; NSCLC=non‐small cell lung cancer; NTRK=neurotrophic tyrosine receptor kinase; RET=rearranged during transfection; ROS1=ROS proto-oncogene 1.
  • NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.